Methods of predicting clinical course and treating multiple sclerosis
AssigneeTel HaShomer Medical Research Infrastructure and Services Ltd.
InventorsAnat ACHIRON, Michael GUREVICH
Life of this patent
Estimating the term…
Loading patent…
AssigneeTel HaShomer Medical Research Infrastructure and Services Ltd.
InventorsAnat ACHIRON, Michael GUREVICH
Estimating the term…
Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.
A method of monitoring an efficiency of an anti multiple sclerosis (MS) drug in treating a subject diagnosed with a typical relapsing remitting multiple sclerosis (RRMS) course, the method comprising:
A method of treating a subject diagnosed with multiple sclerosis, the method comprising
A kit identified for classifying a disease course in a subject diagnosed with multiple sclerosis (MS) comprising a probeset comprising a plurality of oligonucleotides and no more than 10 oligonucleotides, wherein said plurality of oligonucleotides comprise an oligonucleotide that specifically recognizes a polynucleotide of at least one gene involved in the RNA polymerase pathway;
Dependencies are inferred from the claim text.